Eliav Barr, Merck Research Laboratories CMO
Merck pays Moderna $250M to continue Keytruda, cancer vaccine combo studies
After nearly six years of working together, Merck and Moderna are taking the next step in their cancer vaccine partnership.
Merck is opting into a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
